← Eichor
Study identifier: NCT05889013 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Utility of PCD Diagnostics to Improve Clinical Care

Condition: Primary Ciliary Dyskinesia  ·  Sponsor: Connecticut Children's Medical Center

PhaseN/A
Planned participants50
Who can joinAll sexes, 2 Years to no upper limit
Healthy volunteersNo

About this study

This cross-sectional and longitudinal observational study is to gather data on the utility of tests that are used to make a diagnosis of primary ciliary dyskinesia (PCD). There is new testing available, called nasal nitric oxide testing, that non-invasively measures nitric oxide levels in the sinus cavity. Individuals with PCD characteristically have low levels, but this testing does not have extensive data from everyday clinical practice. The objective of this proposal is to improve the diagnostic approach to children and adults with clinical concerns for primary ciliary dyskinesia (PCD).

This description comes directly from the study's public registry record.

Talk to the study team

Melanie S Collins, MD  ·  860-545-9440  ·  mcollin@connecticutchildrens.org

Sigrid M Almeida, BS  ·  8608375343  ·  salmeida@connecticutchildrens.org

Always discuss trial participation with your own doctor first.

Locations (1)

Pulmonary DivisionHartford, Connecticut, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05889013